LianBio, Inc. (LIANY)
Market Closed
11 Aug, 20:00
OTC PINK OTC PINK Primary $
0. 04
-0
-1.2821%
$
4.21M Market Cap
- P/E Ratio
- Div Yield
79,392 Volume
- Eps
$ 0.04
Previous Close Want to track LIANY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LIANY closed today lower at $0.04, a decrease of -1.2821% from yesterday's close, completing a monthly decrease of -19.7917% or -$0.01. Over the past 12 months, LIANY stock lost -59.4737%.
LIANY pays dividends to its shareholders, with the most recent payment made on Mar 14, 2024. The next estimated payment will be in 14 Mar 2024 on Mar 14, 2024 for a total of $4.8.
The last earnings report, released on Mar 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
LianBio, Inc. (LIANY) FAQ
What is the stock price today?
The current price is $0.04.
On which exchange is it traded?
LianBio, Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is LIANY.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.21M.
Has LianBio, Inc. ever had a stock split?
No, there has never been a stock split.
LianBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Adam Leo Stone CEO | OTC PINK Exchange | 53000N108 CUSIP |
| US Country | 163 Employees | 14 Mar 2024 Last Dividend | - Last Split | - IPO Date |
Overview
LianBio is a prominent biopharmaceutical entity concentrated on pioneering and marketing therapeutic solutions across distinct domains such as cardiovascular, oncology, ophthalmology, and inflammatory diseases within China and other Asian markets. Established in 2019 and with its headquarters in Princeton, New Jersey, LianBio stands out for its dedication to addressing critical unmet medical needs. Through strategic partnerships with other innovators in the biopharma sector, the company leverages groundbreaking scientific advancements to strengthen its portfolio and broaden its impact across the Asian healthcare landscape.
Products and Services
- mavacamten: A pioneering medication targeting obstructive and non-obstructive hypertrophic cardiomyopathy along with heart failure with preserved ejection fraction, focusing on the improvement of cardiac function and patient quality of life.
- TP-03: Developed in partnership with Tarsus Pharmaceuticals, Inc., this therapeutic is aimed at treating Demodex blepharitis and meibomian gland disease, offering a potential solution for these common but often challenging to manage eye conditions.
- NBTXR3: In collaboration with Nanobiotix S.A., LianBio is advancing this radioenhancer designed for direct injection into malignant tumors before standard radiotherapy, targeting head and neck squamous cell carcinoma and solid tumors, to amplify treatment efficacy.
- Infigratinib: Focuses on treating cholangiocarcinoma at both second-line and first-line stages and gastric cancers, aiming to offer patients better outcomes through targeted therapy.
- BBP-398: A potential new therapy for solid tumors, highlighting LianBio's investment in innovative oncology solutions to address hard-to-treat cancers.
- Omilancor and NX-13: Two promising treatments for inflammatory bowel diseases, specifically ulcerative colitis and Crohn's disease, reflecting LianBio's commitment to addressing gastroenterological disorders.
- LYR-210: Tailored for chronic rhinosinusitis, this treatment represents LianBio's foray into addressing chronic inflammatory conditions affecting the nasal passages and sinuses.
- Sisunatovir: Targeting respiratory syncytial virus, this antiviral therapy underscores LianBio's dedication to combating infectious diseases and their impact on public health.
Contact Information
Address: 103 Carnegie Center Drive
Phone: 609 486 2308
Website: https://www.lian-medical.com/#
